Genetic approaches to sarcoma diagnosis

Julia A. Bridge

Research output: Contribution to journalArticle

Abstract

Bone and soft-tissue sarcomas are diagnostically challenging. Increasing recognition of the specific genetic and chromosomal abnormalities inherent in these tumors and the growing use of cytogenetic and molecular genetic procedures have significantly improved the accuracy of sarcoma diagnosis and provided valuable information on the histopathogenesis of these neoplasms. This article discusses the advantages and limitations of three such approaches - conventional cytogenetic analysis, molecular cytogenetic analysis or fluorescence in situ hybridization, and reverse transcription polymerase chain reaction analysis - and which testing method may be most suitable for different clinical scenarios.

Original languageEnglish (US)
Pages (from-to)525-528
Number of pages4
JournalCommunity Oncology
Volume3
Issue number8
DOIs
StatePublished - Aug 2006

Fingerprint

Cytogenetic Analysis
Sarcoma
Fluorescence In Situ Hybridization
Cytogenetics
Chromosome Aberrations
Reverse Transcription
Molecular Biology
Neoplasms
Bone and Bones
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Genetic approaches to sarcoma diagnosis. / Bridge, Julia A.

In: Community Oncology, Vol. 3, No. 8, 08.2006, p. 525-528.

Research output: Contribution to journalArticle

Bridge, Julia A. / Genetic approaches to sarcoma diagnosis. In: Community Oncology. 2006 ; Vol. 3, No. 8. pp. 525-528.
@article{c61463f142c14ae7aa6b29db216f916c,
title = "Genetic approaches to sarcoma diagnosis",
abstract = "Bone and soft-tissue sarcomas are diagnostically challenging. Increasing recognition of the specific genetic and chromosomal abnormalities inherent in these tumors and the growing use of cytogenetic and molecular genetic procedures have significantly improved the accuracy of sarcoma diagnosis and provided valuable information on the histopathogenesis of these neoplasms. This article discusses the advantages and limitations of three such approaches - conventional cytogenetic analysis, molecular cytogenetic analysis or fluorescence in situ hybridization, and reverse transcription polymerase chain reaction analysis - and which testing method may be most suitable for different clinical scenarios.",
author = "Bridge, {Julia A.}",
year = "2006",
month = "8",
doi = "10.1016/S1548-5315(11)70746-X",
language = "English (US)",
volume = "3",
pages = "525--528",
journal = "Community Oncology",
issn = "1548-5315",
publisher = "BioLink Communications",
number = "8",

}

TY - JOUR

T1 - Genetic approaches to sarcoma diagnosis

AU - Bridge, Julia A.

PY - 2006/8

Y1 - 2006/8

N2 - Bone and soft-tissue sarcomas are diagnostically challenging. Increasing recognition of the specific genetic and chromosomal abnormalities inherent in these tumors and the growing use of cytogenetic and molecular genetic procedures have significantly improved the accuracy of sarcoma diagnosis and provided valuable information on the histopathogenesis of these neoplasms. This article discusses the advantages and limitations of three such approaches - conventional cytogenetic analysis, molecular cytogenetic analysis or fluorescence in situ hybridization, and reverse transcription polymerase chain reaction analysis - and which testing method may be most suitable for different clinical scenarios.

AB - Bone and soft-tissue sarcomas are diagnostically challenging. Increasing recognition of the specific genetic and chromosomal abnormalities inherent in these tumors and the growing use of cytogenetic and molecular genetic procedures have significantly improved the accuracy of sarcoma diagnosis and provided valuable information on the histopathogenesis of these neoplasms. This article discusses the advantages and limitations of three such approaches - conventional cytogenetic analysis, molecular cytogenetic analysis or fluorescence in situ hybridization, and reverse transcription polymerase chain reaction analysis - and which testing method may be most suitable for different clinical scenarios.

UR - http://www.scopus.com/inward/record.url?scp=33749180335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749180335&partnerID=8YFLogxK

U2 - 10.1016/S1548-5315(11)70746-X

DO - 10.1016/S1548-5315(11)70746-X

M3 - Article

AN - SCOPUS:33749180335

VL - 3

SP - 525

EP - 528

JO - Community Oncology

JF - Community Oncology

SN - 1548-5315

IS - 8

ER -